166 related articles for article (PubMed ID: 8608487)
1. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma.
Takeda H; Akakura K; Masai M; Akimoto S; Yatani R; Shimazaki J
Cancer; 1996 Mar; 77(5):934-40. PubMed ID: 8608487
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
4. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of androgen receptor content in advanced prostate cancer.
Magi-Galluzzi C; Xu X; Hlatky L; Hahnfeldt P; Kaplan I; Hsiao P; Chang C; Loda M
Mod Pathol; 1997 Aug; 10(8):839-45. PubMed ID: 9267828
[TBL] [Abstract][Full Text] [Related]
6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
7. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis.
Tilley WD; Lim-Tio SS; Horsfall DJ; Aspinall JO; Marshall VR; Skinner JM
Cancer Res; 1994 Aug; 54(15):4096-102. PubMed ID: 7518349
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
10. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
11. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
12. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
15. Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Cancer Res; 1995 Jul; 55(14):3068-72. PubMed ID: 7541709
[TBL] [Abstract][Full Text] [Related]
16. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.
Szabó J; Bartók K; Krenács T; Szepesváry Z; Szende B
Anticancer Res; 2009 Feb; 29(2):681-4. PubMed ID: 19331222
[TBL] [Abstract][Full Text] [Related]
17. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
[TBL] [Abstract][Full Text] [Related]
18. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
19. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
20. [Clinical studies on endocrine therapy for prostatic carcinoma (4): Initial response to endocrine therapy and prognosis].
Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Ohshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
Hinyokika Kiyo; 1991 Nov; 37(11):1505-10. PubMed ID: 1767773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
